Provenienza dei contatti di primo grado di Anil Bhushan
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Anil Bhushan tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Director of Finance/CFO | |
GELESIS INC | Biotechnology | Director/Board Member | |
Atlantic Healthcare Plc
Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Chief Operating Officer | |
MYREXIS, INC. | Financial Conglomerates | Director/Board Member | |
Integrated Plasmonics Corp.
Integrated Plasmonics Corp. SemiconductorsElectronic Technology Integrated Plasmonics Corp. operates as a nanotechnology company. The company was founded on February 4, 2011 and is headquartered in San Francisco, CA. | Semiconductors | Founder | |
Insight Venture Management LLC
Insight Venture Management LLC Investment ManagersFinance Insight Venture Management LLC (Insight Venture Partners) is a private equity/ venture capital subsidiary of Insight Holdings Group LLC founded in 1995 by Jeffrey L. Horing and Jerry Fred Murdock. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
CRV LLC
CRV LLC Investment ManagersFinance Charles River Ventures, Inc. is a venture capital firm founded in 1970. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
University of Dayton | College/University | Undergraduate Degree | |
University of Illinois | College/University | Undergraduate Degree | |
University of Bristol | College/University | Graduate Degree | |
University of Michigan | College/University | Doctorate Degree | |
The University of Law Ltd. | College/University | Graduate Degree | |
VERASTEM, INC. | Biotechnology | Chief Executive Officer | |
Rhapsody Biologics, Inc.
Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | Biotechnology | Director/Board Member | |
University of California | College/University | Doctorate Degree | |
SevenOaks Biosystems LLC
SevenOaks Biosystems LLC Medical SpecialtiesHealth Technology Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016. | Medical Specialties | Director/Board Member | |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | Biotechnology | Chief Executive Officer | |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | Pharmaceuticals: Major | Director/Board Member | |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
Alzeca Biosciences, Inc.
Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici. | Miscellaneous Commercial Services | Founder | |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member | |
MBC Biolabs
MBC Biolabs Miscellaneous Commercial ServicesCommercial Services MBC Biolabs is a company that provides space and equipment to life-science startups, allowing them to be fast, focused, and frugal. The company has four sites, one in the Mission Bay neighborhood in San Francisco, CA, and two campuses in other locations. MBC Biolabs has partnerships with leading pharmaceutical and life-science companies, as well as a built-in venture capital firm, Mission BioCapital, which provides entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Since opening in 2013, MBC Biolabs has helped launch and grow over 300 companies, which have brought 153 programs to the clinic, produced 13 approved diagnostics, and raised over $143 billion. | Miscellaneous Commercial Services | Chief Operating Officer | |
Dyno Therapeutics, Inc.
Dyno Therapeutics, Inc. BiotechnologyHealth Technology Dyno Therapeutics, Inc. engages in the development of therapeutics technologies. It develops technologies for safe, efficient and targeted in vivo delivery of new gene therapies and genome editing therapies. The company was founded by Kelsic Eric David and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
Unlearn.AI, Inc.
Unlearn.AI, Inc. Packaged SoftwareTechnology Services Unlearn.AI, Inc. develops machine learning technology for clinical drug trails. It offers clinical trial design, synthetic control arms, and super-powered subgroup analysis. The company was founded by Aaron Smith, Charles K. Fisher, and Jonathan Walsh in 2017 and is headquartered in San Francisco, CA. | Packaged Software | Director/Board Member | |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | Miscellaneous Commercial Services | Founder | |
Switch Therapeutics, Inc.
Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | Pharmaceuticals: Major | Director/Board Member | |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | Miscellaneous Commercial Services | Director/Board Member | |
EQRX, INC. | Pharmaceuticals: Major | Founder | |
Gameto, Inc.
Gameto, Inc. BiotechnologyHealth Technology Gameto, Inc. is a biotechnology company based in New York, NY that focuses on developing novel treatment solutions for women's health, starting with infertility. The company's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. The company's goal is to improve assisted fertility outcomes, make the medical burden of menopause optional, and redefine female reproductive health by testing and developing drugs for ovarian disease. Gameto is led by CEO Dina Radenkovic, a physician-turned-entrepreneur, and Chairman Martin Varsavsky, a serial entrepreneur and founder of the largest fertility network, Prelude Fertility. | Biotechnology | Director/Board Member | |
ImmuneBridge, Inc.
ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Biotechnology | Director/Board Member | |
ArrePath, Inc.
ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Information Technology Services | Director/Board Member | |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Pharmaceuticals: Major | Director/Board Member | |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Miscellaneous Commercial Services | Founder | |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | Medical Specialties | Director/Board Member | |
Capacity Bio, Inc.
Capacity Bio, Inc. BiotechnologyHealth Technology Capacity Bio, Inc. is a biotech company based in an undisclosed location. The American company is focused on developing a first-in-class mitophagy therapeutic platform and an advanced analytical toolkit to characterize mitochondria. The company was founded by Amy Wang, Stan Louie, and Kathy Rodgers, and the CEO is Kenneth Nicholas Horne. | Biotechnology | Director/Board Member | |
Vecprobio Inc.
Vecprobio Inc. Packaged SoftwareTechnology Services Vecprobio Inc. develops manufacturing technologies and tools for gene therapy. The company is based in San Diego, CA. The company was founded in 2022. Daniel Gibbs has been the CEO of the company since 2022. | Packaged Software | Chairman | |
Foundery Innovations, Inc.
Foundery Innovations, Inc. BiotechnologyHealth Technology Foundery Innovations, Inc. develops transformative immunotherapies for immune-based diseases. The private company is based in San Francisco, CA. Foundery Innovations was founded in 2021 by Michel Streuli, Venkataraman Sriram, Max Krummel. Michel Streuli has been the CEO since 2021. | Biotechnology | Founder | |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 43 |
Regno Unito | 4 |
Canada | 2 |
Settori
Health Technology | 27 |
Consumer Services | 7 |
Commercial Services | 7 |
Finance | 5 |
Technology Services | 4 |
Posizioni
Director/Board Member | 28 |
Founder | 9 |
Independent Dir/Board Member | 5 |
Chief Operating Officer | 5 |
Corporate Officer/Principal | 4 |
Contatti più connessi
Insiders | |
---|---|
Robert M. Forrester | 25 |
Dylan Morris | 14 |
Leah Makley | 5 |
Max Krummel | 5 |
Robin Mansukhani | 2 |
Rachel Hatano | 1 |
- Borsa valori
- Insiders
- Anil Bhushan
- Connessioni Società